ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.
Many cancer patients take multiple drugs as part of their treatment – often for many months or years. While drugs are not the only costly part of cancer treatment, finding ways to reduce these costs for patients and payers will significantly reduce the overall cost burden of cancer.
This Survivor Views survey examined access to and affordability of cancer care. Survivors report insurance-related barriers to obtaining prescriptions, and lower-income respondents in particular have difficulty affording them. 24% of respondents have received a surprise medical bill, 60% of which were more than $500.
Biological drugs, commonly referred to as biologics, are a class of drugs that are produced using a living system, such as a microorganism, plant cell, or animal cell. Like all drugs, biologics are regulated by the United States Food and Drug Administration (FDA).
For an individual with specific health care needs – like cancer patients and survivors – the drugs covered by a health plan and corresponding cost sharing for each drug is important information when choosing health insurance. However, to make an informed choice, formulary information must be disclosed to the individual.
The incidence of cancer increases with age and thus the Medicare program is vitally important to millions of Americans who are undergoing active cancer treatment, are cancer survivors or who have not yet developed cancer.
While ACS CAN supports South Carolina expanding Medicaid, we oppose the current proposal for a severely limited expansion with work requirements and an enrollment cap. We urge CMS to reject this proposal.
Medicaid provides access to life-saving care for people in America fighting cancer, especially low-income individuals primarily from rural and underserved communities.
ACS CAN and Manatt Health estimated the amount of coverage loss and funding losses that would be caused if the House-passed budget reconciliation bill became law.
